NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has received approval from the New York State Department of Health to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.

In early August, the company said that its ThyraMir thyroid cancer classifier test had been approved by New York State, and that it planned to submit ThyGenX for approval as well.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.